173 related articles for article (PubMed ID: 10870643)
1. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy.
Suzuki Y; Nakano T; Ohno T; Abe A; Morita S; Tsujii H
J Cancer Res Clin Oncol; 2000 Jun; 126(6):332-6. PubMed ID: 10870643
[TBL] [Abstract][Full Text] [Related]
2. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
[TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
4. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
5. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.
Pras E; Willemse PH; Canrinus AA; de Bruijn HW; Sluiter WJ; ten Hoor KA; Aalders JG; Szabo BG; de Vries EG
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):23-32. PubMed ID: 11777619
[TBL] [Abstract][Full Text] [Related]
6. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix.
Liu CZ; Zeng HX; Zhao JJ; Rong Y; Mo ZL; Li LA; Zhang JQ
Int J Gynecol Cancer; 2017 Jun; 27(5):994-1000. PubMed ID: 28498239
[TBL] [Abstract][Full Text] [Related]
7. [Investigation of the usefulness of CYFRA 21-1 as a tumor marker in squamous cell carcinomas of the head and neck].
Sano K; Kataoka S; Katoh T; Kawauchi H; Morikawa S
Nihon Jibiinkoka Gakkai Kaiho; 1997 Jul; 100(7):790-7. PubMed ID: 9277101
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy.
Wakatsuki M; Suzuki Y; Nakamoto S; Ohno T; Ishikawa H; Kiyohara H; Kiyozuka M; Shirai K; Nakayama Y; Nakano T
J Gastroenterol Hepatol; 2007 May; 22(5):715-9. PubMed ID: 17444861
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1.
Pradier O; Hille A; Schmiberger H; Hess CF
Cancer Radiother; 2002 Feb; 6(1):15-21. PubMed ID: 11899676
[TBL] [Abstract][Full Text] [Related]
11. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
[TBL] [Abstract][Full Text] [Related]
12. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations.
Callet N; Cohen-Solal Le Nir CC; Berthelot E; Pichon MF
Eur J Gynaecol Oncol; 1998; 19(1):50-6. PubMed ID: 9476060
[TBL] [Abstract][Full Text] [Related]
13. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels.
Kashiwabara K; Nakamura H; Esaki T
Clin Chim Acta; 2000 Apr; 294(1-2):105-13. PubMed ID: 10727677
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of cytokeratin 19 fragments in cervical cancer.
Nasu K; Etoh Y; Yoshimatsu J; Matsu T; Narahara H; Miyakawa I
Gynecol Obstet Invest; 1996; 42(4):267-70. PubMed ID: 8979101
[TBL] [Abstract][Full Text] [Related]
15. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.
Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH
Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
[TBL] [Abstract][Full Text] [Related]
17. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
18. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
19. Serum level of cytokeratin 19 fragment (CYFRA 21-1) indicates tumour stage and prognosis of squamous cell carcinoma of the oesophagus.
Tsuchiya Y; Onda M; Miyashita M; Sasajima K
Med Oncol; 1999 Apr; 16(1):31-7. PubMed ID: 10382940
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.
Puthucode-Easwaran S; Naik R; Athavale R; Handley G; Lopes A; Godfrey K; Hatem M
J Obstet Gynaecol; 2005 Jul; 25(5):486-8. PubMed ID: 16183586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
